{"database": "lobbying", "table": "lobbying_activities", "rows": [[623420, "edc0d6ea-a086-4fb9-997b-930437d02d57", "Q2", "CAPITOL HILL CONSULTING GROUP", 72053, "PHRMA", 2008, "second_quarter", "PHA", "General pharmaceutical issues, including but not limited to: The Federal Food and Drug and Cosmetic Act; the Hatch-Waxman Act; patent reform; drug importation; and drug safety", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2008-07-09T11:15:55-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["623420"], "units": {}, "query_ms": 0.3586300299502909, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}